<SEC-DOCUMENT>0001178913-22-004413.txt : 20221223
<SEC-HEADER>0001178913-22-004413.hdr.sgml : 20221223
<ACCEPTANCE-DATETIME>20221223081014
ACCESSION NUMBER:		0001178913-22-004413
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20221223
FILED AS OF DATE:		20221223
DATE AS OF CHANGE:		20221223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MediWound Ltd.
		CENTRAL INDEX KEY:			0001593984
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36349
		FILM NUMBER:		221483381

	BUSINESS ADDRESS:	
		STREET 1:		42 HAYARKON STREET
		CITY:			YAVNE
		STATE:			L3
		ZIP:			8122745
		BUSINESS PHONE:		97289324010

	MAIL ADDRESS:	
		STREET 1:		42 HAYARKON STREET
		CITY:			YAVNE
		STATE:			L3
		ZIP:			8122745
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2228918.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 22.10.1.5080
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C.&#160; 20549<br>
      ______________________</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">FORM 6-K</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT&#160;OF FOREIGN PRIVATE ISSUER</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Pursuant to Rule 13a-16 or 15d-16 of the<br>
      Securities Exchange Act of 1934</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">For the month of December 2022</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Commission File Number: 001-36349</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25;"><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><u><font style="font-size: 16pt; font-family: 'Times New Roman',Times,serif; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">MediWound Ltd.&#160;</font></u><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><br>
      (Translation of registrant&#8217;s name into English)</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">42 Hayarkon Street</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Yavne, 8122745 Israel</div>
    <div style="text-align: center; line-height: 1.25;">&#160;(Address of principal executive offices)</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Form 20-F &#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Form 40-F &#9744;<br>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
      101(b)(1):&#160;&#160; __</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
      101(b)(7):&#160;&#160; __</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXPLANATORY NOTE</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On December 23, 2022, MediWound Ltd. (the &#8220;Company&#8221;) issued a press release entitled &#8220;MediWound Expands NexoBrid&#8217;s
      Global Presence with Marketing Approval in Japan&#8221;. A copy of this press release is attached to this Form 6-K as Exhibit 99.1.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The content of this report on Form 6-K (including the information contained in Exhibit 99.1, but excluding quotes of
      senior management of the Company) is hereby incorporated by reference into the Company&#8217;s Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 and
      August 9, 2022&#160;(Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-195517, 333-210375, 333-230487, 333-236635, 333-255784, and &#160;333-266697 respectively)&#160;and
      on&#160;Form F-3 filed with the SEC on May 25, 2022 (Registration No. 333-265203), and on Form F-1 filed with the SEC on November 10, 2022 (Registration No. 333-268297).</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SIGNATURE</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
      signed on its behalf by the undersigned, thereunto duly authorized.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; border-collapse: separate; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">

          <tr>
            <td valign="top" style="width: 50%;">&#160;</td>
            <td valign="top" style="width: 38%;" colspan="2">MEDIWOUND LTD.</td>
            <td valign="top" style="width: 12%;">&#160;</td>
          </tr>
          <tr>
            <td valign="top" style="width: 50%;">&#160;</td>
            <td valign="top" style="width: 3%;">&#160;</td>
            <td valign="top" style="width: 35%;">&#160;</td>
            <td valign="top" style="width: 12%;">&#160;</td>
          </tr>
          <tr>
            <td valign="top" align="left" style="width: 50%; padding-bottom: 2px;">Date: December 23, 2022</td>
            <td valign="top" style="width: 3%; padding-bottom: 2px;">
              <div align="left" style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt">By: </div>
            </td>
            <td valign="top" nowrap="nowrap" align="left" style="width: 35%; border-bottom: #000000 2px solid">/s/ Boaz Gur-Lavie</td>
            <td valign="top" style="width: 12%; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="top" style="width: 50%;">&#160;</td>
            <td valign="top" style="width: 3%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" align="left" style="width: 35%;">Name: Boaz Gur-Lavie</td>
            <td valign="top" style="width: 12%;">&#160;</td>
          </tr>
          <tr>
            <td valign="top" style="width: 50%;">&#160;</td>
            <td valign="top" style="width: 3%;">&#160;</td>
            <td valign="top" style="width: 35%;">Title:&#160;&#160; Chief Financial Officer</td>
            <td valign="top" style="width: 12%;">&#160;</td>
          </tr>
          <tr>
            <td valign="top" style="width: 50%;">&#160;</td>
            <td valign="top" style="width: 3%;">&#160;</td>
            <td valign="top" style="width: 35%;">&#160;</td>
            <td valign="top" style="width: 12%;">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div><br>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXHIBIT INDEX</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">The following exhibit is filed as part of this Form 6-K:&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u><br>
        </u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="ze7729396d08d4a6a947d24b98bd1a7c6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 72pt; vertical-align: top;">
            <div> <u>Exhibit</u></div>
            <div> <br>
            </div>
            <div><a href="exhibit_99-1.htm">99.1</a></div>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div> <u>Description</u></div>
            <div> <br>
            </div>
            <div><a href="exhibit_99-1.htm">Press release dated December 23, 2022 titled &#8220;MediWound
                Expands NexoBrid&#8217;s Global Presence with Marketing Approval in Japan&#8221;.</a></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="text-align: center; text-indent: -72pt; margin-left: 72pt; line-height: 1.25;"><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 22.10.1.5080
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">
          <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; text-align: right;"><u><font style="font-weight: bold;">Exhibit 99.1</font></u><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><img src="image00001.jpg"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">MediWound Expands NexoBrid&#8217;s Global Presence with </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Marketing Approval in Japan</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">Japan is the first country in the world to approve NexoBrid for people of all ages;</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">pediatric and adult populations</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">Exclusive marketing and distribution agreement with Kaken Pharmaceutical Co., Ltd.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">YAVNE, Israel, December 23, 2022</font>
      - MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that its partner, Kaken Pharmaceutical Co., Ltd. has gained
      marketing approval of NexoBrid<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> in Japan. Kaken Pharmaceutical, a top ranked Japanese pharmaceutical company, has the exclusive right to market and distribute NexoBrid in Japan. Kaken Pharmaceutical expects to launch NexoBrid in the summer
      of 2023.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted NexoBrid marketing authorization for non-surgical eschar
        removal of deep-partial and full-thickness thermal burns for the adult and pediatric population. NexoBrid is approved under the orphan drug designation granted by the MHLW as a priority review for unmet medical needs.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;We look forward to partnering with Kaken
        Pharmaceutical and are confident that their proven track record of achieving market penetration will maximize the medical and commercial potential of NexoBrid in Japan,&#8221; stated&#160;Ofer Gonen, Chief Executive Officer of&#160;MediWound. &#8220;This approval
        further supports our global commercialization strategy to expand the use of NexoBrid to international markets via collaborations with local partners and through additional marketing approvals.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">Hiroyuki Horiuchi, President and Representative Director of Kaken Pharmaceutical said, &#8220;We are very excited to partner with MediWound
        and bring NexoBrid to patients in Japan. Broad evidence-based clinical studies and firsthand experience of leading experts worldwide show that NexoBrid will play a major role in the future of burn care. We look forward to making it the standard of
        care in Japan.&#8221;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">About NexoBrid</div>
    </div>
    <div style="text-align: justify; line-height: 1.25;">NexoBrid<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (concentrate of proteolytic enzymes enriched in bromelain) is a topically administered biological product that
      enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns within four hours of application without harming viable tissue. NexoBrid is approved in 43 countries, in the&#160;European Union&#160;and
      other international markets, and is at registration-stage with the&#160;Food and Drug Administration&#160;(FDA) with a PDUFA target date set as of January 1, 2023. NexoBrid is supported by the U.S. Biomedical Advanced Research and Development Authority
      (BARDA). NexoBrid has been designated as an orphan biologic drug in&#160;the United States,&#160;European Union&#160;and other international markets.&#160;Vericel&#160;holds an exclusive license for North American commercial rights to NexoBrid. The pivotal Phase 3 U.S.
      clinical study (DETECT) of NexoBrid in adult patients with deep partial-and full-thickness thermal burns up to 30% of total body surface area met its primary endpoint of complete eschar removal compared to gel vehicle as well as all secondary
      endpoints compared to standard of care (SOC), including shorter time to eschar removal, a lower incidence of surgical eschar removal and lower blood loss during eschar removal. Safety endpoints, including the key safety endpoint of non-inferiority in
      time to complete wound closure compared with patients treated with SOC, were also achieved. In addition, the twelve-month and twenty-four-month follow-up safety data of cosmesis and function were found to be comparable between the treatment and SOC
      arms, and no new safety signals were observed. In addition,&#160;MediWound&#160;announced positive results from Phase 3 pediatric study (CIDS), evaluating the efficacy and safety compared with standard-of-care (SOC). The study met its three primary endpoints
      with a high degree of statistical significance. NexoBrid demonstrated a significant reduction in time to achieve complete eschar removal and significant reduction in wound area requiring surgical excision (surgical need) while demonstrating
      non-inferiority to SOC in quality of scars. The European Medicines Agency (EMA) has validated for review the Type II Variation submitted by MediWound in order to expand the current approved indication for NexoBrid into the pediatric population.
      MediWound expects a decision from the European Commission in the first quarter of 2023.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About Kaken Pharmaceutical Co., Ltd.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">Kaken Pharmaceutical Co., Ltd. (TYO: 4521) is a specialty
          pharmaceutical company in Japan with strong experience in developing and commercializing novel pharmaceuticals in the fields of orthopedics and dermatology. The Company concentrates its R&amp;D resources in the areas of immune system, nervous
          system and infectious diseases.&#160; <u>https://www.kaken.co.jp/english/</u></div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About MediWound Ltd.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="text-align: justify; line-height: 1.25;">MediWound is a biopharmaceutical company that develops, manufactures, and commercializes novel, cost effective, bio-therapeutic
      solutions for tissue repair and regeneration. Our strategy is to leverage our enzymatic technology platform, focusing on next-generation bioactive therapies for burn care, wound care, and tissue repair.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">NexoBrid, our commercial orphan biological product for non-surgical eschar removal of deep-partial and full-thickness thermal burns, is
      a bromelain-based biological product containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within four hours without harming surrounding viable tissue. NexoBrid is currently marketed in the European Union and other
      international markets. It is at the registration-stage with the United States Food and Drug Administration (FDA) with a target PDUFA date set for January 1, 2023. NexoBrid is supported by the U.S. Biomedical Advanced Research and Development
      Authority (BARDA).</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">EscharEx, based on the same active pharmaceutical ingredient as NexoBrid, is our next-generation bioactive topical therapeutic under
      development for the debridement of chronic and hard-to-heal wounds. Results from Phase 2 studies show that EscharEx is significantly more effective and faster than SOC, or placebo control, in debridement of VLUs and DFUs. It has demonstrated a
      favorable safety and tolerability profile. MediWound has initiated discussions with the FDA regarding the EscharEx pivotal Phase 3 study design.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">MW005 is our topical biological drug under development for the treatment of low-risk Basal Cell Carcinoma (BCC). Its proprietary
        formulation is designed for safe and easy self-administration. It contains the same active pharmaceutical ingredient as NexoBrid and EscharEx. In a Phase I/II open-label, multicenter, randomized clinical trial conducted in the U.S., MW005 was shown
        to be safe, well-tolerated, and an effective treatment for BCC with patients demonstrating complete clinical and histological clearance of target lesions.</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Committed to innovation, we are dedicated to improving standard of care and enhancing patient lives. For more information, please visit
      <u>www.mediwound.com</u>.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Cautionary Note Regarding Forward-Looking Statements</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-style: italic;">MediWound&#160;cautions you that all
            statements other than statements of historical fact included in this press release that address activities, events, or developments that we expect,&#160;believe,&#160;or anticipate will or may occur in the future are forward-looking statements.&#160;Although
            we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current&#160;expectations about future events affecting us and are subject to risks, assumptions,&#160;uncertainties,&#160;and factors, all of
            which are difficult to predict and many of which are beyond our control.&#160; Actual results may differ materially from those expressed or implied by the forward-looking statements in this press release.&#160; These statements are often, but are not
            always, made through the use of words or phrases such as &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;continues,&#8221; &#8220;believe,&#8221; &#8220;guidance,&#8221; &#8220;outlook,&#8221; &#8220;target,&#8221; &#8220;future,&#8221; &#8220;potential,&#8221; &#8220;goals&#8221; and similar words or phrases, or future
            or conditional verbs such as &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; or similar expressions</font>.</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;"><br>
        Specifically, this press release contains forward-looking statements concerning the anticipated commercial potential, progress, development, study design,
            expected data timing, objectives anticipated timelines and expectations of our products and product candidates. Among the factors that may cause results to be materially different from those stated herein are the inherent uncertainties
            associated with the market potential and acceptance of our products and product candidates, and uncertain, lengthy and expensive nature of the product development process; the timing and conduct of our studies of our products and product
            candidates, including the timing, progress and results of current and future clinical studies, and our research and development programs; the approval of regulatory submission by the European Medicines Agency, FDA or by any other regulatory
            authority, our ability to obtain marketing approval of our products and product candidates in the&#160;U.S.&#160;or other markets. For Example the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of our
            products and products; our expectations regarding future growth, including our ability to develop new products; risks related to our contracts with BARDA our ability to maintain adequate protection of our intellectual property; competition
            risks; the need for additional financing; the impact of government laws and regulations and the impact of the current global macroeconomic climate on our ability to source supplies for our operations or our ability or capacity to manufacture,
            sell and support the use of our products and product candidates in the future.</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;"><br>
        These and other significant factors are discussed in greater detail in MediWound&#8217;s annual report on Form 20-F for the year ended&#160;December 31, 2021, filed with
            the&#160;Securities and Exchange Commission&#160;(&#8220;SEC&#8221;) on&#160;March 17, 2022, Quarterly Reports on Form 6-K and other filings with the&#160;SEC&#160;from time-to-time. These forward-looking statements reflect MediWound&#8217;s current views as of the date hereof
            and&#160;MediWound&#160;undertakes, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after the date of this release except as
            required by law.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <table cellspacing="0" cellpadding="2" border="0" id="z1d67291b944b4be1b5ed4eca6a8e4929" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.99%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;"><u><font style="font-weight: bold;">Contacts</font>:</u></div>
          </td>
          <td style="width: 50.01%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Monique Kosse</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.99%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Boaz Gur-Lavie</div>
          </td>
          <td style="width: 50.01%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Managing Director</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.99%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Chief Financial Officer</div>
          </td>
          <td style="width: 50.01%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">LifeSci Advisors</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.99%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">MediWound Ltd.</div>
          </td>
          <td style="width: 50.01%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">212-915-3820</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.99%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;"><u>ir@mediwound.com</u></div>
          </td>
          <td style="width: 50.01%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">monique@lifesciadvisors.com</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !4 .,# 2(  A$! Q$!_\0
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%** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
